☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Daiichi Sankyo
PharmaShots Weekly Snapshots (March 11 – March 15, 2024)
March 15, 2024
Daiichi Sankyo Submits NDA of Datopotamab Deruxtecan to the MHLW for the Treatment of Advanced Breast Cancer
March 14, 2024
Daiichi Sankyo and AstraZeneca Reports the US FDA’s Acceptance of BLA for Datopotamab Deruxtecan (Dato-DXd) to Treat Non-Small Cel...
February 19, 2024
Top 20 Life Sciences Deals of 2023 by Total Deal Value
February 16, 2024
Daiichi Sankyo Submits sNDA for Ezharmia to the Japan MHLW for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
January 31, 2024
Daiichi Sankyo Entered into a Development and Commercialization Agreement with Merck for Three Daiichi Sankyo DXd ADCs
October 20, 2023
Load more...
Back to Home